E-drug: Concession to national pharmaceutical companies
-------------------------------------------------------
Dear E-druggers,
It has been the policy in the past and still is to give a price
margin concession to national pharmaceutical suppliers of 10 to 15%.
It is understood that the rationale of such a policy is to give
protection to a national industry in order for it to be able to compete
and to develop.
To me it appears that national suppliers even without such a
concession are at an advantage compared with international suppliers
due to lower transportation and other costs. Therefore, the concession
is even higher.
A company with a subsidiary in a neighbouring country can transfer
products to the country in which the drug will be sold and get a
better price.
Can somebody enlighten me with regard to the rationale of giving a
concession to national pharmaceutical suppliers, and if the rationale
has been to give protection to national industries has the policy
worked as intended?
Which indicators have been used to measure the achievement of policy
objectives?
Best regards
Ole Frank Nielsen
NIELSEN CONSULT Phone: +45 33919030
Skindergade 23, 3. Cellular: +45 20144814
1159 Copenhagen K Fax: +45 33919032
Denmark E-mail: olefrank@inet.uni-c.dk
--
Send mail for the `E-Drug' conference to `e-drug@usa.healthnet.org'.
Mail administrative requests to `majordomo@usa.healthnet.org'.
For additional assistance, send mail to: `owner-e-drug@usa.healthnet.org'.